Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
SFRP5 Biologics Sequence Review Report 2026: Secreted frizzled-related protein 5 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SFRP5 Biologics Sequence Review Report 2026: Secreted frizzled-related protein 5 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SFRP5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SFRP4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SFRP4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SFRP4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SFRP2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SFRP2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SFRP2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SFRP1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SFRP1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SFRP1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SELP Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SELP Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SELP sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SELL Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SELL Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SELL sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SDC4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SDC4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SDC4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SDC3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SDC3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SDC3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SDC2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SDC2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SDC2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SDC1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SDC1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SDC1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SCN11A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SCN11A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SCN11A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SCN10A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SCN10A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SCN10A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →